Advertisement

Dopamine Antagonists as Anti-Emetics and as Stimulants of Gastric Motility

  • Brian McRitchie
  • Christine M. McClelland
  • Stephen M. Cooper
  • David H. Turner
  • Gareth J. Sanger
Part of the NATO ASI Series book series (volume 80)

Abstract

Dopamine antagonists are commonly used to treat the symptoms of psychosis, where abnormal dopaminergic neuro-transmission in the brain is thought to be the primary cause of the illness1,2. Some dopamine antagonists however are not “anti-psychotic”, because they do not easily cross the blood-brain barrier or they only weakly antagonise the dopamine receptors involved in psychosis3. Among this latter group of antagonists are drugs which are used clinically to inhibit nausea and vomiting caused by a large number of different stimuli. Examples of such drugs include the substituted benzamides metoclopramide and clebopride, and the butyrophenone derivative, domperidone (Fig. 1).

Keywords

Gastric Emptying Dopamine Receptor Test Meal Gastrointestinal Motility Gastric Motility 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    L. L. Iversen, Dopamine receptors in the brain, Science. 188:1084 (1975).PubMedCrossRefGoogle Scholar
  2. 2.
    P. Seeman, Brain dopamine receptors, Pharmaco1. Rev. 32:229 (1981).Google Scholar
  3. 3.
    M. Stanley, A. Lautin, J. Rotrosen, and S. Gershon, Anti psychotic efficacy of metoclopramide: Do DA/neuroleptic receptors mediate the action of anti-psychotic drugs? IRCS/Med. Sci. 7:322 (1979).Google Scholar
  4. 4.
    J. Perrot, G. Nahas, C. Laville, and A. Debay, Substituted benzamides as antiemetics, in: "Treatment of cancer chemotherapy-induced nausea and vomiting", D. S. Poster, J. S. Penta and S. Bruno, ed., Masson Publishing USA, Inc. (1982)Google Scholar
  5. 5.
    H. L. Borison, Area postrema? Chemoreceptor trigger zone for vomiting - Is that all? Life Sei. 14:1807 (1974).CrossRefGoogle Scholar
  6. 6.
    H. L. Borison and S. C. Wang, Physiology and pharmacology of vomiting, Pharmacol. Rev. 5:193 (1953).PubMedGoogle Scholar
  7. 7.
    H. L. Borison and L. E. McCarthy, Physiologic basis of nausea and vomiting, "Treatment of cancer chemotherapy-induced nausea and vomiting", D. S. Poster, J. S. Penta and S. Bruno, ed., Masson Publishing USA, Inc. (1982).Google Scholar
  8. 8.
    R. M. Pinder, R. N. Brogden, P. R. Sawyer, T. M. Speight, and G. S. Avery, Metoclopramide: A review of its pharmacological properties and clinical use. Drugs, 12:81 (1976).PubMedCrossRefGoogle Scholar
  9. 9.
    R. N. Brogden, A. A. Carmine, R. C. Heel, T. M. Speight, and G. S. Avery, Domperidone: A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic, Drugs, 24:360 (1982).PubMedCrossRefGoogle Scholar
  10. 10.
    R. A. Harrington, C. W. Hamilton, R. N. Brogden, J. A. Linkewich, J. A. Romankiewicz, and R. C. Heel, Metoclopramide: An updated review of its pharmacological properties and clinical use. Drugs, 25:451 (1983).PubMedCrossRefGoogle Scholar
  11. 11.
    K. Schulze-Delrieu, Metoclopramide, Gastroenterol. 77:768 (1979).Google Scholar
  12. 12.
    D. J. Roberts, The pharmacological basis of the therapeutic activity of clebopride and related substituted benzamides, Curr. Ther. Res. 31 (Suppl.):l (1982).Google Scholar
  13. 13.
    A. Wauquier, C. J. E. Niemegeers, and P. A. J. Janssen, Neuropharmacological comparison between domperidone and metoclopramide, Jap. J. Pharmac. 31:305 (1981).CrossRefGoogle Scholar
  14. 14.
    R. J. Gralla, L. M. Itri, S. E. Pisko, A. E. Squillante, D. P. Kelson, D. W. Braun, L. A. Bordin, T. J. Braun, and C. W. Young, Antiemetic efficacy of high-dose metoclopramide: Randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New Eng. J. Med. 305:905 (1981).PubMedCrossRefGoogle Scholar
  15. 15.
    R. A. Joss, A. Goldhirsch, K. W. Brunner, and R. L. Galeazzi, Sudden death in cancer patient on high-dose domperidone. Lancet. 1:1019 (1982).PubMedCrossRefGoogle Scholar
  16. 16.
    J. H. Szurszewski and C. F. Code, Activity fronts of the canine small intestine, Gastroenterol. 54:1304 (1968).Google Scholar
  17. 17.
    C. F. Code and J. F. Schlegel, The gastrointestinal interdigestive housekeeper, Proc. 4th Int. Sym. Gastrointestinal Motility. Mitchell, Vancouver, pp 631–634 (1974).Google Scholar
  18. 18.
    A. R. Cooke, Control of gastric emptying and motility, Gastroenterol. 68:804 (1975).Google Scholar
  19. 19.
    A. Lane, A. C. Ivy, and E. K. Ivy, Response of the chronic gastric fistula rat to histamine. Am. J. Physiol. 190:221 (1957).PubMedGoogle Scholar
  20. 20.
    J. N. Hunt and M. T. Knox, The regulation of gastric emptying of meals containing citric acid and salts of citric acid, J. Physiol. 163:34 (1962).PubMedGoogle Scholar
  21. 21.
    C. M. McClelland and G. J. Sanger, Effects of metoclopramide and domperidone on cholinergic responses in rat isolated stomach, Br. J. Pharmac. 77, Proc. Suppl: 539P (1982).Google Scholar
  22. 22.
    J. B. Furness and M. Costa, The adrenergic innervation of the gastrointestinal tract, Ergeb. Physiol. 69:1 (1974).Google Scholar
  23. 23.
    P. L. R. Andrews, D. Grimdy, and I. N. C. Lawes, The role of the vagus and splanchnic nerves in the regulation of intragastric pressure in the ferret, J. Physiol. 307:401 (1980).PubMedGoogle Scholar
  24. 24.
    J. B. Furness and M. Costa, Indentification of gastrointestinal neurotransmitters, in: "Handb. Exp. Pharmacol, 59, Mediators and Drugs in Gastrointestinal Motility. I.", G. Bertaccini, ed., Springer-Verlag, Berlin, Heidelberg, New York (1982).Google Scholar
  25. 25.
    J. M. Van Neuten, Is dopamine an inhibitory modulator of gastric motility? Trends in Pharmacological Sciences. May:233 (1980).Google Scholar
  26. 26.
    H. A. Sahyoun, B. Costall, and R. J. Naylor, Catecholamineinduced relaxation and contraction of the lower oesophageal and pyloric sphincters of guineapig stomach: Modification by domperidone, J. Pharm. Pharmacol. 34:318 (1982).PubMedCrossRefGoogle Scholar
  27. 27.
    R. A. Lefebvre, J. P. Blancquaert, J. L. Willems, and M. G. Bogaert, In vitro study of the inhibitory effects of dopamine on the rat gastric fundus, Naunyn-Schmiedeberg’s Arch. Pharmacol. 322:228 (1983).CrossRefGoogle Scholar
  28. 28.
    G. J. Sanger, Mechanisms by which metoclopramide can increase gastrointestinal motility,in: ‘This book’.Google Scholar
  29. 29.
    G. N. Woodruff, A. O. Eikhawad, and R. M. Pinder, Long lasting stimulation of locomotor activity produced by the intraventricular injection of a cyclic analogue of dopamine into conscious mice, Eur. J. Pharmacol. 25:80 (1974).CrossRefGoogle Scholar
  30. 30.
    K. Uvnas-Wallensten and M. Goiny, Dopaminergic control of gastro intestinal hormones, in: "Apomorphine and other dopaminomimetics. Vol. 1: Basic Pharmacology", G. L. Gessa and G. U. Corsini, ed.. Raven Press, New York (1981).Google Scholar
  31. 31.
    D. L. Cochlin, Dystonie reactions due to metoclopramide and phenothiazines resembling tetanus, Br. J. Clin. Pract. 28:201 (1974).PubMedGoogle Scholar
  32. 32.
    D. Tarsy, J. D. Parkes, and C. D. Marsden, Metoclopramide and pimozide in Parkinson’s disease and levodopa-induced dyskineasias, J. Neurol. Neurosurg. and Psychiatry. 38:331 (1975).CrossRefGoogle Scholar
  33. 33.
    P. Protais, J. Costentin, and J. C. Schwartz, Climbing behaviour induced by apomorphine in mice: A simple test for the study of dopamine receptors in striatum, Psychopharmacol. 50:1 (1976).CrossRefGoogle Scholar
  34. 34.
    M. T. Litchfield and F. Wilcoxon, A simplified method of eval uating dose-effect experiments, J. Pharmac. 96:99 (1949).Google Scholar
  35. 35.
    P. Sol, B. Pelet, and J-P. Guignard, Extrapyramidal reactions to domperidone. Lancet. 2(8198):802 (1980).CrossRefGoogle Scholar
  36. 36.
    M. Gance, J. Bury, L. Burton, and P. J. Delwaide, Syndrome neurodysleptique induit par le domperidone, La Nouvelle Presse Medicale. 11:2298 (1982).Google Scholar
  37. 37.
    R. M. Macleod, Regulation of prolactin secretion, in: "Frontiers in Neuroendocrinology, IV"., L. Martini and W. F. Ganong, ed., Raven Press, New York (1976).Google Scholar
  38. 38.
    P. A. Cann, N. W. Read, and C. D. Holdsworth, Galactorrhoea as side effect of domperidone, Br. Med. J. 286:1395 (1983).CrossRefGoogle Scholar
  39. 39.
    C. M. McClelland, B. McRitchie, and D. H. Turner, BRL 20627: A non-dopaminergic blocking stimulant of gastric motility, Br. J, Pharmac. 80, Proc. Suppl:569P (1983).Google Scholar
  40. 40.
    C. M. McClelland and G. J. Sanger, Increased cholinergic respon ses with BRL 20627 in rat isolated stomach: Comparison with metoclopramide, Br. J. Pharmac. 80, Proc. Suppl:568P (1983).Google Scholar
  41. 41.
    G. J. Reynolds, Metoclopramide in young children, Br, Med. J. 2 (6153):1713 (1978).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • Brian McRitchie
    • 1
  • Christine M. McClelland
    • 1
  • Stephen M. Cooper
    • 1
  • David H. Turner
    • 1
  • Gareth J. Sanger
    • 1
  1. 1.Medicinal Research CentreBeecham PharmaceuticalsHarlow, EssexUK

Personalised recommendations